Allosteric inhibitor of WEE1 kinase
View Patent ↗Disclosed is a method for selecting a cancer therapeutic for a patient that involves assaying a tumor biopsy sample from the subject to detect PAXIP1 expression, and selecting a WEE1 inhibitor as the cancer therapeutic if PAXIP1 is detected in the tumor biopsy sample.
1. A compound having a structure below:
wherein:
R 1 is —NH 2 or a salt thereof; and
R 2 and R 3 are independently for each occurrence selected from hydrogen, hydroxyl, C 1 -C 6 alkyl, halogen, amino, C 1-6 alkyl amine, or a salt thereof.
2. The compound of claim 1 , having a structure below:
3. A method for inhibiting a WEE1 epigenetic activity, the method comprising administering an effective amount of a compound according to claim 1 .
4. A method for treating cancer having WEE1 epigenetic activity in a subject, the method comprising administering to the subject an effective amount of a compound according to claim 1 .
5. The method of claim 4 , wherein the cancer is glioblastoma (GBM), melanoma, prostate or triple negative breast cancers.